Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NYSEMKT:AMPE
- CUSIP: 03209T10
- Web: ampiopharma.com/
- Market Cap: $31.2 million
- Outstanding Shares: 57,242,000
- 50 Day Moving Avg: $0.57
- 200 Day Moving Avg: $0.76
- 52 Week Range: $0.47 - $1.14
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.87
- P/E Growth: 0.000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.09 per share
- Price / Book: 6.19
- EBIDTA: ($12,450,000.00)
- Return on Equity: -131.07%
- Return on Assets: -62.52%
- Average Volume: 505,325 shs.
- Short Ratio: 15.12
Frequently Asked Questions for Ampio Pharmaceuticals (NYSEMKT:AMPE)
What is Ampio Pharmaceuticals' stock symbol?
Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AMPE."
How were Ampio Pharmaceuticals' earnings last quarter?
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) issued its quarterly earnings data on Tuesday, February, 24th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.01. View Ampio Pharmaceuticals' Earnings History.
Who are some of Ampio Pharmaceuticals' key competitors?
Some companies that are related to Ampio Pharmaceuticals include Flex Pharma (FLKS), Verona Pharma Plc (VRP), Endocyte (ECYT), Xenon Pharmaceuticals (XENE), Actinium Pharmaceuticals (ATNM), Avacta Group Plc (AVCT), Imprimis Pharmaceuticals (IMMY), Rexahn Pharmaceuticals (RNN), Motif Bio PLC (MTFB), Akari Therapeutics PLC (AKTX), pSivida Corp. (PSDV), OptiBiotix Health PLC (OPTI), Zosano Pharma Corporation (ZSAN), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), Midatech Pharma PLC (MTPH), Bellerophon Therapeutics (BLPH) and Aeglea BioTherapeutics (AGLE).
Who are Ampio Pharmaceuticals' key executives?
Ampio Pharmaceuticals' management team includes the folowing people:
- Michael Macaluso, Chairman of the Board, Chief Executive Officer
- Thomas E. Chilcott III, Interim Chief Financial Officer
- David Bar-Or M.D., Chief Scientific Officer, Director
- Gregory A. Gould CPA, Treasurer, Secretary
- Vaughan Lennox Clift M.D., Chief Regulatory Affairs Officer
- Philip H. Coelho M.D., Independent Director
- Richard B. Giles, Independent Director
- David R. Stevens Ph.D., Independent Director
How do I buy Ampio Pharmaceuticals stock?
Shares of Ampio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ampio Pharmaceuticals' stock price today?
MarketBeat Community Rating for Ampio Pharmaceuticals (NYSEMKT AMPE)MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ampio Pharmaceuticals stock can currently be purchased for approximately $0.55.
Consensus Ratings for Ampio Pharmaceuticals (NYSEMKT:AMPE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
(Data available from 7/21/2015 forward)
|6/30/2016||Janney Montgomery Scott||Reiterated Rating||Positive|
Earnings History for Ampio Pharmaceuticals (NYSEMKT:AMPE)Earnings History by Quarter for Ampio Pharmaceuticals (NYSEMKT AMPE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Current Year EPS Consensus Estimate: $-0.610 EPS
Next Year EPS Consensus Estimate: $-0.190 EPS
Dividend History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Latest Headlines for Ampio Pharmaceuticals (NYSEMKT:AMPE)
|Ampio Hosting Conference Call, Wednesday, July 12, 4:30 pm EDT|
finance.yahoo.com - July 6 at 5:09 PM
|Ampio Pharma (AMPE) Begins Dosing in Final Pivotal Clinical Trial for Ampion BLA|
www.streetinsider.com - June 23 at 4:06 PM
|Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion™ BLA|
finance.yahoo.com - June 22 at 12:18 PM
|Ampio Announces Appointment of Interim Chief Financial Officer|
finance.yahoo.com - June 12 at 4:34 PM
|Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering|
finance.yahoo.com - June 7 at 8:41 PM
|Ampio Pharma (AMPE) Says Human Macrophage Study Results Accepted for Presentation at AAST Meeting|
www.streetinsider.com - May 6 at 1:33 AM
|Ampion™ Human Macrophage Study Results Accepted for Presentation at the 2017 Annual AAST Meeting in Baltimore|
finance.yahoo.com - May 5 at 3:31 PM
|Ampio Initiates Pivotal Trial of Ampion™|
finance.yahoo.com - May 1 at 9:38 AM
|Ampio Pharmaceuticals Amends Warrant Agreement|
us.rd.yahoo.com - March 28 at 9:31 AM
|AMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and|
biz.yahoo.com - March 28 at 9:31 AM
|Ampio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™|
us.rd.yahoo.com - March 23 at 11:14 PM
|Ampio Pharma (AMPE) Announces Issuance of China Patent - StreetInsider.com|
www.streetinsider.com - March 23 at 3:45 PM
|Colorado biotech's accountants express 'substantial doubt' about firm's future|
www.bizjournals.com - March 23 at 3:45 PM
|Update - Ampio Pharmaceuticals Provides Corporate Update|
us.rd.yahoo.com - March 22 at 8:34 PM
|Ampio Pharma (AMPE) Provides Corporate Update; Locust Walk to Serve as Strategic Advisor - StreetInsider.com|
www.streetinsider.com - March 21 at 3:54 PM
|Ampio Pharmaceuticals Provides Corporate Update|
us.rd.yahoo.com - March 20 at 3:50 PM
|Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST - PR Newswire (press release)|
www.prnewswire.com - March 1 at 8:12 AM
|Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST|
finance.yahoo.com - March 1 at 8:12 AM
|Colorado biotech's drug for knee pain shows a 'promising effect'|
www.bizjournals.com - February 28 at 9:22 AM
|Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for …|
finance.yahoo.com - February 28 at 9:22 AM
|Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee|
us.rd.yahoo.com - February 28 at 9:22 AM
|8:31 am Ampio Pharma announcs that the Office of Tissue & Advanced Therapies has recently provided additional guidance for the path to approval of Ampion as a treatment for pain due to severe Osteoarthritis of the knee|
us.rd.yahoo.com - February 28 at 9:22 AM
|Ampio Pharma (AMPE) Receives Guidance from the FDA on Ampion - StreetInsider.com|
www.streetinsider.com - February 27 at 3:38 PM
|Ampio Pharmaceuticals - Running On Fumes|
seekingalpha.com - February 2 at 2:12 AM